- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.04. | Cyclerion Therapeutics, Inc. - 10-K/A, Annual Report | - | SEC Filings | ||
| 18.04. | Cyclerion Therapeutics, Inc. - S-4, Registration of securities, business combinations | - | SEC Filings | ||
| 02.04. | Penny Stock CYCN Surged More Than 300% Yesterday. Why, And Should You Chase the Rally Here? | 7 | Barchart.com | ||
| 02.04. | Alzheimer's biotech Korsana to go public via reverse merger | - | pharmaphorum | ||
| 01.04. | Korsana Biosciences and Cyclerion Therapeutics to Merge, Operate Under Korsana Name | 3 | Contract Pharma | ||
| 01.04. | Cyclerion Therapeutics: $380 Million Financing To Merge With Korsana Biosciences And Advance Alzheimer's Pipeline | 1 | pulse2.com | ||
| 01.04. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| CYCLERION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.04. | Alzheimer's-focused Korsana to use Cyclerion reverse merger to go public | 3 | FierceBiotech | ||
| 01.04. | Morning Market Movers: Cyclerion Therapeutics, Binah Capital Group, Target Hospitality Corp., nCino See Big Swings | 766 | AFX News | WASHINGTON COUNTY (dpa-AFX) - At 8:20 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before... ► Artikel lesen | |
| 01.04. | Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc. Announce Merger Agreement | 116 | Business Wire | Combined company to operate as Korsana Biosciences and to advance Korsana's potential best-in-class therapeutics to treat neurodegenerative diseases
Korsana's lead program KRSA-028 is a next-generation... ► Artikel lesen | |
| 16.03. | Korsana Biosciences Taps Dr. Mark Vignola as CFO | 1 | Contract Pharma | ||
| 22.02. | Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer's Drug | 1 | MedCity News | ||
| 18.02. | Korsana Biosciences Raises $175M in Funding | 1 | FinSMEs | ||
| 17.02. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 17.02. | Cyclerion receives FDA feedback on depression treatment development | 6 | Investing.com | ||
| 06.01. | Cyclerion Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.01. | Cyclerion und Medsteer kooperieren bei der Entwicklung einer neuartigen Depressionstherapie | 1 | Investing.com Deutsch | ||
| 05.01. | Cyclerion-Aktie mit massivem Kurssprung nach strategischer Kooperation mit Medsteer | 9 | Investing.com Deutsch | ||
| 05.01. | Cyclerion partners with Medsteer to advance depression treatment platform | 1 | Investing.com | ||
| 05.01. | Cyclerion Therapeutics, Inc.: Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression | 163 | GlobeNewswire (Europe) | - Cyclerion Strengthens Development of Closed-Loop Anesthetic Platform through Strategic Collaboration Agreement with Medsteer - - Comprehensive Business Update and Path to Initiating Phase 2 Proof-of-Concept... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| RECURSION PHARMACEUTICALS | 3,040 | 0,00 % | Recursion Q1 2026 slides: AI pipeline advances amid revenue challenges | ||
| BEAM THERAPEUTICS | 29,530 | 0,00 % | H.C. Wainwright reiterates Beam Therapeutics stock rating at buy | ||
| CORMEDIX | 7,032 | +9,84 % | CorMedix, Inc.: Cormedix Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | ? Q1 2026 Net Revenue of $127.4 million ? ? Q1 2026 Net Income of $38.6 million; Adjusted EBITDA of $70.0 million ? - Company raises FY 2026 Revenue and Adjusted EBITDA Guidance - ? Conference Call... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 0,194 | -2,66 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| REPLIMUNE | 3,909 | -13,73 % | Replimune surges day after FDA Commissioner Makary resigns | ||
| MATINAS BIOPHARMA | 0,610 | +3,39 % | Matinas BioPharma Holdings, Inc. - 10-Q, Quarterly Report | ||
| ABSCI | 5,530 | 0,00 % | Absci outlines ABS-201 interim 13-week data in H2 2026 while adding ABS-202 and funding plans into H1 2028 | ||
| CINGULATE | 4,380 | -10,98 % | Cingulate reports Q1 loss, raises cash runway into 2027 | ||
| STRUCTURE THERAPEUTICS | 39,810 | 0,00 % | Structure Therapeutics reports Q1 results | ||
| NURIX THERAPEUTICS | 16,010 | -1,05 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg... ► Artikel lesen | |
| BIOXYNE | 0,040 | 0,00 % | Biotech vor der Neubewertung? Warum Bioxyne mit Cannabis und Psychedelika ins Rampenlicht rückt | ||
| SILO PHARMA | 0,412 | +5,59 % | Silo Pharma, Inc.: Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury | New initiative from Silo Pharma designed to align with federal actions to accelerate mental health innovation using psychedelic medicines Silo Pharma targets unmet need in a drug market with no FDA-approved... ► Artikel lesen | |
| COMPASS THERAPEUTICS | 1,985 | 0,00 % | Compass Therapeutics to Participate in Upcoming May Investor Events | ||
| HOTH THERAPEUTICS | 0,654 | 0,00 % | Hoth Therapeutics, Inc.: Hoth Therapeutics Secures European Authorization in Spain for HT-001 Phase 2a Trial as Interim Data Show Strong Efficacy in Cancer Patients | Regulatory Clearance in Spain Advances Randomized, Placebo-Controlled Study; Patients Show Meaningful Reductions in EGFR-Inhibitor Skin Toxicities with No Treatment... ► Artikel lesen | |
| MAXCYTE | 0,870 | +0,58 % | MAXCYTE, INC. - 10-Q, Quarterly Report |
Das Unternehmen CYCLERION THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 3,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CYCLERION THERAPEUTICS INC finden Sie auf Wallstreet Online.